oralcancernews.org
Palbociclib plus cetuximab shows antitumor activity among head and neck cancer subset
Source: www.healio.com Author: Adkins D, et al. A combination of palbociclib and cetuximab demonstrated substantial antitumor activity among patients with platinum- or cetuximab-resistant HPV-unrelated head and neck squamous cell carcinoma, according to results of a multigroup phase 2 trial published in The Lancet Oncology. “Currently, effective therapeutic options for patients with cetuximab-resistant HNSCC are few. Traditional chemotherapy has